Imipenem/Cilastatin Aptapharma

Imipenem/cilastatin, the active ingredient in Imipenem/Cilastatin Aptapharma, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It provides broad‑spectrum coverage against Gram‑positive, Gram‑negative and anaerobic bacteria and is employed in hospitalized patients with serious infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft‑tissue infections, febrile neutropenia, and bacterial meningitis.

GNH USA supplies Imipenem/Cilastatin Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, research institutions and clinics worldwide.

Imipenem/cilastatin is used for serious bacterial infections that require intravenous therapy.

Complicated intra‑abdominal infections: provides broad‑spectrum bacterial clearance in the abdominal cavity. Complicated urinary tract infections: eradicates resistant Gram‑negative pathogens in the urinary system. Skin and soft‑tissue infections: treats deep or necrotizing infections caused by mixed flora. Febrile neutropenia: offers rapid bactericidal activity in immunocompromised patients. Bacterial meningitis: penetrates the cerebrospinal fluid to eliminate meningitic organisms.

Adverse reactions to Imipenem/Cilastatin may occur; they are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis after infusion. - Diarrhea: loose stools, usually self‑limiting. - Rash: transient skin erythema or pruritus.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Anaphylaxis: severe allergic reaction with hypotension and airway compromise. - Clostridioides difficile colitis: antibiotic‑associated colitis requiring prompt treatment.

When prescribing Imipenem/Cilastatin, clinicians should consider several safety precautions.

Renal function: adjust dose in patients with impaired renal function. Seizure risk: monitor patients with central nervous system disorders or receiving high doses. Allergy: avoid in patients with known hypersensitivity to carbapenems or beta‑lactams. Pregnancy: use only if potential benefit justifies risk to fetus. Drug interactions: review concomitant medications for major interactions. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/Cilastatin can interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Valproic acid: co‑administration may reduce valproate levels and precipitate seizures. - Probenecid: may increase imipenem plasma concentrations, raising toxicity risk. - Carbapenem plus high‑dose penicillins: potential antagonism reducing antibacterial effect.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance electrolyte disturbances, especially sodium and potassium. - Oral contraceptives: efficacy may be reduced; advise additional contraceptive measures.